medigraphic.com

2021, Number 4

<< Back Next >>

Enf Infec Microbiol 2021; 41 (4)

Out-of-pocket expenses of patients with HIV/AIDS attending a control program in Montería, Colombia

Hernández SJM, Doria REM, Herrera AL, Arboleda RM, Gil RJM, Martínez SLM

Language: Spanish
References: 18
Page: 148-151
PDF size: 161.17 Kb.


ABSTRACT

Introduction. The human immunodeficiency virus is an infectious agent that has caused more than 34 million deaths since its discovery.
ObjectiveTo estimate the out-of-pocket expenses assumed by patients with a diagnosis of HIV/AIDS who attend a program to control their disease in the city of Montería.
Methods. Descriptive study. To determine out-of-pocket expenses, the methodology defined by Coyle and Drummond and the methodological guide for conducting economic evaluations within the framework of the Ministry of Health’s Clinical Practice Guidelines were taken into account.
Results. 43 patients participated, average age 36 years, 59% unemployed. Monthly expenses: transportation were an average of 12.83 dollars, the expenses assumed in medical services an average of 20 dollars, with diagnostic studies of 5.85 dollars. They stopped receiving an average of 38.6 dollars. The total expenses assumed by the patients were 73. 44. About 44% received some type of economic benefit from the EPS, IPS or the mayor’s office, for an average value of 4.76 dollars.
Conclusions. The out-of-pocket expenses that patients must assume are very high, sometimes representing up to 83% of their income, which indicates that their illness is behaving as a catastrophic event. Although the national program includes the delivery of antiretroviral drugs, expenditures on other drugs, laboratory tests, and disabilities are impacting patients.


REFERENCES

  1. Sandoval, Dommar de N. et al., “Infección por el virus de la inmunodeficiencia humana (vih) en servicios de medicina”, Rev Soc Ven Microbiol, 2008, 28 (2): 1493-1516.

  2. Phair, J.P. y Murphy, R.L., “Patogenia de la infección por vih”, Actualización diagnóstica y terapéutica en las infecciones por vih/sida, Barcelona, doyma, 1999, pp. 7-14.

  3. Achucarro, S., “Calidad de vida de pacientes con vih/sida y atención integral de enfermería”, Rev Inst Med Trop, 2010, 5 (1): 20-34.

  4. Ahmad, R. y Siliciano, R., “Immunology of hiv-1 infection”, aids and other manifestation of hiv infection, 4ª ed., Madrid, 2003, pp. 259-278.

  5. Lamotte, J., “Infección por vih/sida en el mundo actual”, Medisan, 2014, 18 (7): 993-1013.

  6. Colombia, Ministerio de Salud y Protección Social, “Protocolo de vigilancia en salud pública: vih/sida”, Bogotá, Instituto Nacional de Salud, 2019. Disponible en: https://www.ins.gov.co/buscador-eventos/Lineamientos/ PRO%20vih%20sida_.pdf. Fecha de consulta: 30 de noviembre de 2020.

  7. Onusida, “Comunidades en el centro, la respuesta al vih en América Latina”, Ginebra, onusida, 2019. Disponible en: http://onusidalac.org/1/images/2019-global-aids-update_ latin-america_es.pdf. Fecha de consulta: 30 de noviembre de 2020.

  8. Lopera, M., Escalante, J. y Einarson, T., “Acceso de las personas con vih al sistema de salud colombiano y sus costos relacionados desde una perspectiva individual y familiar, Bogotá, 2010”, Rev Gerenc Polit Salud, 2011, 10 (20): 81-96.

  9. Resolución 5261 de 1994, Bogotá, Ministerio de Salud, 5 de agosto de 1994. Disponible en: https:// www.minsalud.gov.co/Normatividad_Nuevo/RESOLUCI% C3%93N%205261%20DE%201994.pdf. Fecha de consulta: 30 de noviembre de 2020.

  10. Goudge, J. et al., “Coping with the cost burdens of illness: combining qualitative and quantitative methods in longitudinal, household research”, Scandinavian Journal of Public Health, 2007, 69: 181-185.

  11. Coyle, D. y Drummond, M.F., “Analyzing differences in the costs of treatment across centres within economic evaluations”, Int J Technol Assess Health Care, 2001, 17: 155-163.

  12. Davies, L., Coyle, D. y Drummond, M., “Current status of economic appraisal of health technology in the European Community: report of the network. The ec Network on the Methodology of Economic Appraisal of Health Technology”, Soc Sci Med, 1994, 38 (12): 1601-1607.

  13. Guerrero, R., Guevara, C. y Parody, A. (eds)., Guía metodológica para la realización de evaluaciones económicas en el marco de Guías de Práctica Clínica, Bogotá, Fundación Santa Fe, Ministerio de Salud, Instituto de Evaluación Tecnológica en Salud, 2014.

  14. Kumarasamy, N., Venkatesh, K.K., Mayer, K.H. y Freedberg, K., “Financial burden of health services for people with hiv/aids in India”, Indian J Med Res, 2007, 126 (6): 509-517.

  15. Poudel, A.N., Newlands, D. y Simkhada, P., “The economic burden of hiv/aids on individuals and households in Nepal: a quantitative study”, bmc Health Serv Res, 2017, 17 (1): 76.

  16. Kumarasamy, N., Solomon, S., Peters, E., Amalraj, R.E., Purnima, M., Ravikumar, B. et al., “Antiretroviral drugs in the treatment of people living with human immunodeficiency virus: experience in a South Indian tertiary referral centre”, J Assoc Physicians India, 2001, 48: 390-393.

  17. Duraisamy, P., Ganesh, A.K., Homan, R., Kumarasamy, N., Castle, C. Sripriya, P. et al., “Costs and financial burden of care and support services to plha and households in South India”, aids Care, 2006, 18: 121-127.

  18. Riyarto, S., Hidayat, B., Johns, B., Probandari, A., Mahendradhata, Y., Utarini, A. et al., “The financial burden of hiv care, including antiretroviral therapy, on patients in three sites in Indonesia”, Health Policy Plan, 2010, 25 (4): 272-282.




2020     |     www.medigraphic.com